Young child with Doctor

Latest press releases

Thursday, 2 February 2012
AstraZeneca’s new restructuring initiatives to drive productivity and support innovation In conjunction with the publication of its full year 2011 results earlier today, AstraZeneca announced new restructuring initiatives designed to improve productivity and strengthen the company’s commercial, operations and research and development capabilities.
Thursday, 2 February 2012
AstraZeneca PLC Fourth quarter and full year results 2011 David Brennan, Chief Executive Officer said: "Disciplined execution of our strategy has delivered a good performance in 2011 in the face of intensified pricing pressure and generic competition. Our strong cash flow supported a significant increase in cash distributions to shareholders and continued investment to drive future growth and value. While the further expected losses of market exclusivity make for a challenging 2012 outlook, we remain committed to a long-term, focused, R&D based strategy, and today we have announced further steps to drive productivity in all areas to improve returns on our investment in innovation."
Thursday, 19 January 2012
AstraZeneca and Bristol-Myers Squibb receive complete response letter from US Food and Drug Administration for dapagliflozin AstraZeneca and Bristol-Myers Squibb Company today announced that the US Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for investigational compound dapagliflozin for the treatment of type 2 diabetes in adults.
Wednesday, 11 January 2012
AstraZeneca and IMS Health announce real-world evidence collaboration in Europe AstraZeneca today announced that it has entered into a three-year collaboration agreement with IMS Health, the leading provider of information, services and technology for the healthcare sector, to advance the use of real-world evidence based on observational and retrospective studies throughout Europe to inform the delivery of effective and cost-efficient healthcare.
Monday, 9 January 2012
AstraZeneca reaffirms December 2011 financial guidance for 2011 and mid-term planning assumptions for the 2010 to 2014 period During a routine consensus collection process, confidential Company information was inadvertently embedded in a spreadsheet template sent to the sell-side analyst community that follows the Company.  This information is out of date planning information, and does not represent the Company’s view of expected financial performance for the full year 2011 or for future periods.
Tuesday, 20 December 2011
AstraZeneca updates on olaparib and TC-5214 development programmes AstraZeneca today announced that its investigational compound olaparib will not progress into Phase III development for the maintenance treatment of serous ovarian cancer. In addition, AstraZeneca announced that the second RENAISSANCE Phase III study of TC-5214 for patients with major depressive disorder did not meet its primary end point. As a result, AstraZeneca will take pre-tax impairment charges totalling $381.5 million to R&D expense in the fourth quarter of 2011. The company confirms its expectation for full year Core EPS in the range of $7.20 to $7.40, but with the inclusion of these intangible impairments, Core EPS is likely to be in the lower half of this range.
Thursday, 15 December 2011
G-BA issues positive final medical benefit assessment for BRILIQUE in Germany AstraZeneca today announced that the German assessment body, the Federal Joint Committee (G-BA), has issued its final decision regarding the medical benefit of BRILIQUE (ticagrelor).  This positive decision is in line with the preliminary assessment published by the Institute for Quality and Efficiency in Healthcare (IQWiG) in October, with the addition of a new ST-Elevation Myocardial Infarction/Percutaneous Coronary Intervention (STEMI/PCI) sub-group for patients over 75 years or patients with prior stroke or transient ischemic attack (TIA).
Thursday, 8 December 2011
AstraZeneca to acquire generics company to broaden patient access to medicines in China AstraZeneca today announced it has entered into an agreement to acquire Guangdong BeiKang Pharmaceutical Company Ltd, a privately-owned generics manufacturing company, based in Conghua City, Guangdong province, China. The deal will give AstraZeneca access to a portfolio of injectable medicines used to treat infections which AstraZeneca will make available to patients in China.
Wednesday, 7 December 2011
AstraZeneca to streamline US sales organisation AstraZeneca announced today that it will reduce its US sales force by approximately 1,150 leadership positions and sales representatives as part of the company’s ongoing strategy to operate its business more efficiently to best serve patients in the US.
Monday, 5 December 2011
Groundbreaking scientific collaboration gives UK academia access to compounds to advance medical research A wide range of compounds will be made available free of charge to UK medical researchers next year, following a landmark agreement between the Medical Research Council (MRC) and AstraZeneca. In a new type of collaboration, academia will be granted access to 22 compounds, developed by AstraZeneca. Through MRC funding, UK academia will conduct studies to better understand what drives a range of diseases with a view to exploring new treatment opportunities.
Bookmark & Share